Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Assets (2016 - 2025)

Historic Current Assets for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $799000.0.

  • Guided Therapeutics' Current Assets fell 2339.41% to $799000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $799000.0, marking a year-over-year decrease of 2339.41%. This contributed to the annual value of $1.2 million for FY2024, which is 1407.04% down from last year.
  • As of Q3 2025, Guided Therapeutics' Current Assets stood at $799000.0, which was down 2339.41% from $811000.0 recorded in Q2 2025.
  • Over the past 5 years, Guided Therapeutics' Current Assets peaked at $3.5 million during Q3 2022, and registered a low of $799000.0 during Q3 2025.
  • Moreover, its 5-year median value for Current Assets was $1.4 million (2023), whereas its average is $1.6 million.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 70504.2% in 2021, then crashed by 5479.81% in 2023.
  • Quarter analysis of 5 years shows Guided Therapeutics' Current Assets stood at $1.6 million in 2021, then skyrocketed by 83.51% to $3.0 million in 2022, then tumbled by 53.63% to $1.4 million in 2023, then dropped by 14.07% to $1.2 million in 2024, then tumbled by 33.25% to $799000.0 in 2025.
  • Its last three reported values are $799000.0 in Q3 2025, $811000.0 for Q2 2025, and $811000.0 during Q1 2025.